Pulmonary Fibrosis: Lung Scarring and Treatment Options

Understanding Pulmonary Fibrosis: The Mechanism Inside Your Lungs

Think of healthy lung tissue like a sponge—millions of tiny air sacs called alveoli connected by elastic tissue, designed to stretch and collapse thousands of times per day. Now imagine that sponge gradually being wrapped in plastic wrap. The sponge can still hold water, but it can’t stretch anymore, and the exchange between liquid and air becomes inefficient. That’s what pulmonary fibrosis does to your lungs.

The process begins with some kind of injury at the microscopic level. This might be from inhaled particles, chronic inflammation, or in many cases, we simply don’t know what triggered it. In response, your lungs try to heal. But somewhere in that healing cascade, the process goes wrong. Instead of the inflammation resolving, specialized cells called fibroblasts remain activated and overproduce collagen—the protein that forms scar tissue. Fibroblasts transform into myofibroblasts, cells that function like microscopic construction workers that never clock out. They keep building scar tissue, thickening the walls of the alveoli and the tissue around them.

As this scar tissue accumulates, two problems compound simultaneously. First, the walls thicken, so oxygen has to diffuse across a longer distance—like trying to breathe through increasingly thick fabric. Second, the lungs lose their elasticity, so they require more muscular effort just to inflate. Your diaphragm works harder with each breath, consuming more oxygen, which worsens the oxygen deficit. This creates a vicious cycle where the lungs’ damage directly increases the metabolic demands on the lungs themselves.

Causes and Risk Factors: What Actually Triggers Lung Scarring

Here’s where I need to be honest: in roughly 70% of IPF cases, we don’t definitively know what caused it. We call these “idiopathic,” which is medical code for “we’re still figuring this out.” But there are known culprits, and understanding them matters because some are preventable.

Occupational and environmental exposures are major drivers. Asbestos remains the most infamous, but silica dust affects sandblasters, stonemasons, and foundry workers. Metal dust from welding, especially with cobalt or tungsten carbide, causes hard metal lung disease. Hypersensitivity pneumonitis develops from repeated inhalation of organic particles—bird feathers and droppings in pigeon fanciers, mold spores in moldy hay for farmers, or even heated water aerosols from hot tubs and humidifiers.

Smoking history creates paradoxical risk. While smoking causes emphysema, it also increases fibrosis risk in certain genetic backgrounds. Smokers with respiratory bronchiolitis-interstitial lung disease represent a subtype where inflammation and smoking combine to create fibrotic change.

Autoimmune and connective tissue diseases account for recognizable fibrosis. Rheumatoid arthritis causes pulmonary fibrosis in 10% of patients. Systemic sclerosis (scleroderma) produces fibrosis in nearly 80% of cases, though it’s often mild. Lupus, polymyositis, and mixed connective tissue disease all carry fibrosis risk.

Medications and radiation therapy deserve specific mention. Bleomycin, used for lymphomas and testicular cancer, causes dose-dependent lung fibrosis in up to 10% of patients receiving it. Chemotherapy agents like methotrexate can trigger pulmonary fibrosis months or years after treatment. Thoracic radiation for breast cancer or lymphoma damages lung tissue years later.

Here’s the clinical insight most websites miss: gastroesophageal reflux disease (GERD) correlates with IPF progression in ways that go beyond simple aspiration. Some research suggests that chronic microaspiration and repeated acid-induced inflammation in the lower airways may perpetuate the fibrotic process. Patients with IPF who have reflux symptoms warrant aggressive acid suppression, not just symptom management.

Signs and Symptoms: What Patients Actually Experience

Pulmonary fibrosis doesn’t announce itself loudly. It whispers, then gradually speaks louder.

The earliest sign is usually a persistent, dry cough—the kind that feels like it’s coming from deep in the chest rather than the throat. Patients describe it as a cough that produces nothing or just tiny amounts of mucus. It might be worse at night or when talking, laughing, or exercising. Many people attribute this to a lingering cold or allergies for months before seeking evaluation.

Then comes dyspnea on exertion. Initially, it’s subtle. Walking up two flights of stairs becomes noticeably harder. A patient who once jogged might notice they can’t sustain it. The breathlessness is disproportionate to the activity—someone becomes winded doing activities they did easily a year ago. This is often the moment people finally call their doctor, but not before they’ve internally blamed themselves for “getting out of shape” or “getting older.”

As fibrosis progresses, symptoms expand. Fatigue becomes prominent, partly from the extra work of breathing and partly from chronic hypoxemia. Some patients develop clubbing of the fingertips—a thickening and rounding of the nail beds—a sign of chronic lung disease. A small percentage develop cor pulmonale, where the right side of the heart weakens from years of pumping against stiff lungs, leading to ankle swelling and neck vein distention.

Physical examination often reveals fine crackles at the lung bases—that distinctive “Velcro-like” sound doctors hear when listening with a stethoscope, caused by alveoli snapping open and closed. Oxygen saturation at rest might be normal, but drop during a six-minute walk test, which is why that test is diagnostically important.

Diagnosis: The Actual Process of Identification

Diagnosing pulmonary fibrosis requires more than a chest X-ray, and that’s something Sarah’s initial workup didn’t include. The foundational test is high-resolution CT (HRCT) of the chest, which provides exquisite detail of the lung parenchyma. Radiologists look for a “usual interstitial pneumonia” (UIP) pattern: areas of subpleural and basilar predominant fibrosis with traction bronchiectasis—where scarring pulls on airways—and honeycomb appearance where destruction is severe.

Pulmonary function testing measures forced vital capacity (FVC) and diffusing capacity (DLCO). A pattern of restrictive disease—normal or elevated FEV1/FVC ratio but reduced FVC—combined with disproportionately low DLCO (often less than 60% predicted) fits IPF. These numbers matter because they’re used to stage disease severity and predict prognosis.

Blood work screens for autoimmune causes: antinuclear antibody (ANA), rheumatoid factor, anti-CCP antibodies, and anti-topoisomerase I (anti-Scl-70) antibody if systemic sclerosis is suspected. If occupational exposure history suggests it, specific IgG antibodies identify hypersensitivity pneumonitis.

Some patients require bronchoscopy with bronchoalveolar lavage (BAL) to exclude infection or identify a specific diagnosis, though in classic IPF with typical imaging, this is often skipped. A minority undergo lung biopsy—either transbronchial cryobiopsy or video-assisted thoracoscopic surgery (VATS) biopsy—when imaging is atypical and diagnosis remains uncertain. Biopsy samples are examined for architectural distortion, fibrosis patterns, and presence of fibroblast foci, the microscopic evidence of active disease.

The diagnostic journey is often frustrating. Patients may see multiple pulmonologists, repeat imaging, and undergo multiple tests over months before a definitive diagnosis. Some people undergo treatment for suspected asthma or GERD before pulmonary fibrosis is even considered.

Treatment Options: Current Evidence and Specific Medications

Until 2014, there were no medications proven to slow IPF progression. Then FDA approval of pirfenidone changed the conversation. This molecule inhibits transforming growth factor-beta (TGF-β), a key cytokine driving fibroblast activation. In the CAPACITY and ASCEND trials cited by the NIH, pirfenidone reduced lung function decline by approximately 30-35% over 52 weeks compared to placebo. Patients receive 2,403 mg daily in divided doses, and gastrointestinal side effects (nausea, diarrhea) are common enough that slow titration is necessary.

Nintedanib, approved in 2014 after pirfenidone, works differently—it inhibits receptor tyrosine kinases involved in fibroblast proliferation and angiogenesis. The INPULSIS trials showed it reduced FVC decline by about 50% compared to placebo, making it slightly more effective in many analyses. The dose is 150 mg twice daily with food, and diarrhea occurs in roughly 60% of patients but is usually manageable. Some patients tolerate one drug better than the other based on side effect profiles.

Combination therapy—using pirfenidone and nintedanib together—is increasingly used despite lack of head-to-head trials proving superiority. The rationale is mechanistic: different pathways targeted simultaneously. Cost and tolerability remain barriers.

Corticosteroids as monotherapy don’t work for IPF and may worsen outcomes. However, in connective tissue disease-related pulmonary fibrosis (CTD-ILD), combining low-dose prednisone with mycophenolate mofetil (MMF) or azathioprine shows benefit. Immunosuppression makes sense here because the fi